Hess Sonja Y, Zimmermann Michael B, Adou Pierre, Torresani Toni, Hurrell Richard F
Human Nutrition Laboratory, the Swiss Federal Institute of Technology, Zürich, Switzerland.
Am J Clin Nutr. 2002 Apr;75(4):743-8. doi: 10.1093/ajcn/75.4.743.
In many developing countries, children are at high risk of both goiter and iron deficiency anemia. Iron deficiency adversely affects thyroid metabolism and may reduce the efficacy of iodine prophylaxis in areas of endemic goiter.
The aim of this study was to determine whether iron supplementation in goitrous, iron-deficient children would improve their response to iodized salt.
We conducted a randomized, double-blind, placebo-controlled trial in 5-14-y-old children in Côte d'Ivoire. Goitrous, iron-deficient children (n = 166) consuming iodized salt (10-30 mg I/kg salt at the household level) were supplemented with either iron (60 mg Fe/d, 4 d/wk for 16 wk) or placebo. At 0, 1, 6, 12, and 20 wk, we measured hemoglobin, serum ferritin, serum transferrin receptor, whole-blood zinc protoporphyrin, thyrotropin, thyroxine, urinary iodine, and thyroid gland volume (by ultrasonography).
Hemoglobin and iron status at 20 wk were significantly better after iron treatment than after placebo (P < 0.05). At 20 wk, the mean reduction in thyroid size in the iron-treated group was nearly twice that in the placebo group (x +/- SD percentage change in thyroid volume from baseline: -22.8 +/- 10.7% compared with -12.7 +/- 10.1%; P < 0.01). At 20 wk, goiter prevalence was 43% in the iron-treated group compared with 62% in the placebo group (P < 0.02). There were no significant differences between groups in whole-blood thyrotropin or serum thyroxine at baseline or during the intervention.
Iron supplementation improves the efficacy of iodized salt in goitrous children with iron deficiency. A high prevalence of iron deficiency among children in areas of endemic goiter may reduce the effectiveness of iodine prophylaxis.
在许多发展中国家,儿童面临甲状腺肿和缺铁性贫血的高风险。缺铁会对甲状腺代谢产生不利影响,并可能降低地方性甲状腺肿地区碘预防措施的效果。
本研究的目的是确定对患有甲状腺肿的缺铁儿童补充铁剂是否会改善他们对碘盐的反应。
我们在科特迪瓦5至14岁的儿童中进行了一项随机、双盲、安慰剂对照试验。对食用碘盐(家庭层面碘含量为10 - 30 mg I/kg盐)的甲状腺肿缺铁儿童(n = 166)补充铁剂(60 mg Fe/d,每周4天,共16周)或安慰剂。在0、1、6、12和20周时,我们测量了血红蛋白、血清铁蛋白、血清转铁蛋白受体、全血锌原卟啉、促甲状腺激素、甲状腺素、尿碘以及甲状腺体积(通过超声检查)。
铁剂治疗后20周时的血红蛋白和铁状态显著优于安慰剂组(P < 0.05)。在20周时,铁剂治疗组甲状腺大小的平均缩小幅度几乎是安慰剂组的两倍(甲状腺体积相对于基线的x +/- SD百分比变化:-22.8 +/- 10.7%,而安慰剂组为-12.7 +/- 10.1%;P < 0.01)。在20周时,铁剂治疗组的甲状腺肿患病率为43%,而安慰剂组为62%(P < 0.02)。在基线或干预期间,两组之间全血促甲状腺激素或血清甲状腺素没有显著差异。
补充铁剂可提高碘盐对患有甲状腺肿的缺铁儿童的疗效。地方性甲状腺肿地区儿童中铁缺乏的高患病率可能会降低碘预防措施的有效性。